



# THC Global Group

ASX RELEASE (6 MAY 2019)

## THC Global SPP Completed & Appendix 3B

### Key Points:

- Share Purchase Plan closed – final accepted funds of \$2,983,500
- 545 shareholders participated in the SPP

**THC Global Group Limited (THC Global or the Company)** (ASX:THC) is pleased to confirm that following auditing of the applications, the final amount raised in the Share Purchase Plan (SPP) conducted in April 2019 was \$2,983,500 from a total of 545 applicants.

The relevant Appendix 3B for the issuance of the 5,967,000 new Shares under the SPP and the release of restricted securities is attached.

### For further information, please contact:



**Ken Charteris**  
Chief Executive Officer  
e: [corporate@thc.global](mailto:corporate@thc.global)

**Henry Kinstlinger**  
Company Secretary  
e: [corporate@thc.global](mailto:corporate@thc.global)  
p: +61 2 8644 0601

**Sonny Didugu**  
Investors & Media  
e: [media@thc.global](mailto:media@thc.global)  
p: +61 2 8088 4760

### THC Global Group Limited (ASX: THC) [[thc.global](http://thc.global)]

THC Global operates under a 'Farm to Pharma' pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through existing access schemes. Having secured both a significant growing capacity over two grow sites, and an industry-leading pharmaceuticals biomanufacturing facility with attached testing and product development laboratory, THC Global is in prime position to service both domestic patients and the export market. THC Global's commercial partners operate across four continents, supporting future international growth.

In addition to its core medicinal cannabis business, THC Global owns two Canadian companies, being Crystal Mountain Products and Vertical Canna Inc. Crystal Mountain Products operates a revenue generating global hydroponics retailer and distributor of equipment, material, and nutrients to cannabis growers and producers. Vertical Canna Inc is an investment vehicle through which THC Global intends to build, through acquisitions and strategic partnerships, a vertically integrated Canadian cannabis producer and retailer. Vertical Canna's existing asset portfolio includes a land-holding in Nova Scotia, Canada to be developed into a large-scale cannabis production facility.



THC Global Group Limited  
(ASX: THC) ACN: 614 508 039

[thc.global](http://thc.global)

Level 2, 131 Macquarie Street  
Sydney NSW 2000

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

### New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

THC Global Group Limited (ASX: THC)

ABN

33 614 508 039

We (the entity) give ASX the following information.

#### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

1	+Class of +securities issued or to be issued	Fully Paid Ordinary Shares (FPO)
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	5,967,000 FPO
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares.

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

4	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?	Yes, FPO will rank pari passu with existing FPO.
	<p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	\$0.50 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares issued under the Share Purchase Plan conducted in April 2019.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	No.
	If Yes, complete sections 6b – 6h <i>in relation to the +securities the subject of this Appendix 3B</i> , and comply with section 6i	

<sup>+</sup> See chapter 19 for defined terms.

6b	The date the security holder resolution under rule 7.1A was passed	N/A.
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	N/A.
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	N/A.
6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A.
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2	N/A.
6g	If <sup>+</sup> securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the <sup>+</sup> issue date and both values. Include the source of the VWAP calculation.	N/A.
6h	If <sup>+</sup> securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A.
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	19,697,260 Per Rule 7.1  Nil. Per Rule 7.1A
7	<sup>+</sup> Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	6 May 2019

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

	Number	+Class
8	134,745,072	Fully Paid Ordinary Shares
	56,112,524	Options exercisable at \$0.40 expiring 31/12/2019
	Number	+Class
	1,500,000	Unlisted Options exercisable at \$0.40 expiring 31 Dec 19
	666,665	Unlisted Options exercisable at \$0.40 expiring 31 December 2020
	12,000,000	Class B Performance Shares
	2,500,000	Class C Performance Shares
	6,000,000	Class D Performance Shares
	2,250,000	Class A Performance Options
	3,750,000	Class B Performance Options
	175,000	THC001 Employee Performance Options
	250,000	THC002 Employee Performance Options
	550,000	THC003 Employee Performance Options
	1,100,000	THC004 Employee Performance Options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	
	No change to dividend policy.	

---

+ See chapter 19 for defined terms.

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the <sup>1</sup> securities will be offered	N/A
14	<sup>1</sup> Class of <sup>1</sup> securities to which the offer relates	N/A
15	<sup>1</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

---

<sup>1</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of <sup>1</sup>securities  
(*tick one*)

(a)  <sup>1</sup>Securities described in Part 1

(b)  All other <sup>1</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  If the <sup>1</sup>securities are <sup>1</sup>equity securities, the names of the 20 largest holders of the additional <sup>1</sup>securities, and the number and percentage of additional <sup>1</sup>securities held by those holders

36  If the <sup>1</sup>securities are <sup>1</sup>equity securities, a distribution schedule of the additional <sup>1</sup>securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37  A copy of any trust deed for the additional <sup>1</sup>securities

---

<sup>1</sup> See chapter 19 for defined terms.

**Entities that have ticked box 34(b)**

38 Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought	(a) 37,514,450 (b) 24,132,225						
39 <sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	(a) Fully Paid Ordinary Shares ( <b>FPO</b> ) (b) Options exercisable at \$0.40 expiring 31 December 2019 ( <b>THCO</b> )						
40 Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?	(a) FPO ranks equally with existing quoted FPO (b) THCO ranks equally with existing quoted THCO						
If the additional <sup>+</sup> securities do not rank equally, please state: <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>							
41 Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)	End of the restriction period for restricted securities on 4 May 2019						
42 Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	<table border="1" data-bbox="706 1560 1304 1857"> <thead> <tr> <th data-bbox="706 1560 1023 1605">Number</th> <th data-bbox="1023 1560 1304 1605"><sup>+</sup>Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="706 1605 1023 1673">134,745,072</td> <td data-bbox="1023 1605 1304 1673">Fully Paid Ordinary Shares</td> </tr> <tr> <td data-bbox="706 1740 1023 1857">56,112,524</td> <td data-bbox="1023 1740 1304 1857">Options exercisable at \$0.40 expiring 31/12/2019</td> </tr> </tbody> </table>	Number	<sup>+</sup> Class	134,745,072	Fully Paid Ordinary Shares	56,112,524	Options exercisable at \$0.40 expiring 31/12/2019
Number	<sup>+</sup> Class						
134,745,072	Fully Paid Ordinary Shares						
56,112,524	Options exercisable at \$0.40 expiring 31/12/2019						

---

<sup>+</sup> See chapter 19 for defined terms.

### Quotation agreement


- 1 <sup>+Quotation of our additional</sup> <sup>+securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.</sup>
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



(Company Secretary)

Date: 6 May 2019

Print name: Henry Kinstlinger

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	123,701,877
<b>Add</b> the following:	2,066,195 (Aggregate securities issued on conversion of THCO Options under Listing Rule 7.2 exc. 4 in last 12 months)  500,000 (App 3B: 6 July 2018) (Listing Rule 7.4 Approval 15 November 2018)  500,000 (App 3B: 11 July 2018) (Listing Rule 7.4 Approval 15 November 2018)  1,200,000 (App 3B: 13 September 2018) (Listing Rule 7.4 Approval 15 November 2018)  380,000 (App 3B: 28 November 2018) (Listing Rule 10.11 Approval 15 November 2018)  5,967,000 (This App 3B) (Listing Rule 7.2 exc. 15 – Security Purchase Plan)
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	Nil
“A”	134,315,072
<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15

+ See chapter 19 for defined terms.

	[Note: this value cannot be changed]
<b>Multiply "A" by 0.15</b>	20,147,260
<b>Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	450,000 (App 3B – 26 March 2019)
<b>"C"</b>	450,000
<b>Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1</b>	
<p>"A" x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	20,147,260
<p><b>Subtract "C"</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	450,000
<p><b>Total</b> ["A" x 0.15] – "C"</p>	19,697,260 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
“A”  <i>Note: number must be same as shown in Step 1 of Part 1</i>	N/A
<b>Step 2: Calculate 10% of “A”</b>	
“D”	0.10  <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	N/A
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<i>Insert</i> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"><li>• This applies to equity securities – not just ordinary securities</li><li>• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li><li>• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li><li>• It may be useful to set out issues of securities on different dates as separate line items</li></ul>	N/A
“E”	N/A

---

+ See chapter 19 for defined terms.

<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
“A” x 0.10  <i>Note: number must be same as shown in Step 2</i>	N/A
<b>Subtract “E”</b>  <i>Note: number must be same as shown in Step 3</i>	N/A
<b>Total</b> [“A” x 0.10] – “E”	N/A  <i>Note: this is the remaining placement capacity under rule 7.1A</i>

---

+ See chapter 19 for defined terms.